Neurotez has received US patent covering hormone Leptin for treating Alzheimer's disease (AD) resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.
Patent issuance comes as Neurotez completes GMP manufacturing of recombinant Leptin and prepares for IND-enabling studies.
Preclinical in vitro data and in vivo and interventional studies, along with human epidemiological studies, suggest that Leptin can be a promising therapy for the treatment of Alzheimer's disease.
Neurotez president and CEO Nikolaos Tezapsidis said, "The uniqueness of our therapy is that we are dealing with the replacement of an endogenous pluripotent hormone, that we have shown it improves cognition, and ameliorates pathobiology."
Leptin may have a physiologic role as a liporegulatory hormone for neural cells, and several molecular targets have been identified related to metabolic pathways that mediate Leptin's action.
